Tesamorelin did not start life in a lab chasing a peptide trend. It traces back to a decades-long hunt for a single hypothalamic hormone, a search that produced two Nobel laureates before the molecule that would become tesamorelin was ever synthesized. To understand where tesamorelin came from, you have to start with the hormone it imitates.
The GHRH lineage: hypothalamic hormones and a Nobel-era race
Tesamorelin is a synthetic analog of growth-hormone-releasing hormone, or GHRH. That target hormone sits at the end of a long research lineage. In 1977, Roger Guillemin and Andrew V. Schally shared the Nobel Prize in Physiology or Medicine for their work on the peptide hormones produced by the brain, having spent years processing enormous quantities of animal hypothalamic tissue to isolate the neurohormones that govern the pituitary gland.
GHRH itself proved elusive in normal brain tissue. The breakthrough came from an unexpected direction. In 1982, researchers characterized the hormone not from the hypothalamus but from pancreatic tumors that had caused acromegaly. Guillemin and colleagues published the isolation of a 44-amino-acid growth-hormone-releasing factor in Science in November 1982, while a group including Rivier and Vale reported a 40-amino-acid form from a separate tumor in Nature the same year. With the sequence in hand, chemists could finally synthesize human GHRH and study how it prompts the pituitary to release growth hormone.
That was the scientific raw material. The problem was stability. Native GHRH is degraded almost immediately in the bloodstream, cleaved by the enzyme dipeptidyl peptidase-IV, which made the natural peptide impractical as a research or therapeutic tool. Solving that instability is the story of tesamorelin.
Who developed tesamorelin
Tesamorelin was developed by Theratechnologies, Inc., a biopharmaceutical company based in Canada. The molecule carried the internal development code TH9507. Rather than redesign GHRH from scratch, the company’s chemists made a targeted modification: they attached a trans-3-hexenoyl group to the N-terminal tyrosine of the GHRH(1-44) sequence.
That single change was the point of the whole exercise. The added chemical group made the peptide resistant to the dipeptidyl peptidase-IV cleavage that destroys native GHRH, giving tesamorelin a substantially longer half-life in animal and human studies while preserving the core sequence that engages the GHRH receptor. In effect, tesamorelin is stabilized GHRH: the same biological instruction, engineered to survive long enough to act. This design placed it in the broader class of growth-hormone-releasing factor analogs, distinct from growth hormone itself and from the later peptide secretagogues.
Clinical development and the 2010 approval
Theratechnologies studied tesamorelin most extensively in the context of HIV-associated lipodystrophy, a condition in which excess visceral fat accumulates in the abdomen. In a 2007 study published in the New England Journal of Medicine, Falutz and colleagues reported on the metabolic effects of the growth-hormone-releasing factor in patients with HIV. A pooled analysis of two multicenter, double-blind, placebo-controlled Phase 3 trials followed, published in 2010, which documented reductions in visceral adipose tissue alongside increases in circulating IGF-I over the study period.
On November 10, 2010, the U.S. Food and Drug Administration approved tesamorelin under the brand name Egrifta. It was the first treatment the agency approved for the reduction of excess abdominal fat in HIV patients with lipodystrophy. Theratechnologies later brought forward a reformulated version, marketed as Egrifta SV, and subsequent regulatory filings addressed further formulation changes. The approval marked the transition of a stabilized GHRH analog from a chemistry problem into a defined, regulated clinical product.
Where the research record stands
It is worth being precise about what the documented record covers. Tesamorelin’s regulatory approval is narrow and specific: it concerns a defined patient population studied in controlled trials, not a broad endorsement of GHRH analogs for general use. Beyond that indication, tesamorelin appears across the scientific literature as a subject of continued laboratory and clinical investigation into the growth-hormone axis, with much of that work still preliminary or exploratory. The peptide is frequently referenced in research settings precisely because its stabilized design makes it a useful probe for studying GHRH signaling. The history is well documented; the wider science remains an open and active field rather than a settled one.
What makes tesamorelin a clean case study is the straight line running through it: hypothalamic hormone research in the 1970s, the isolation and sequencing of human GHRH in 1982, a single deliberate chemical modification by Theratechnologies, and a 2010 approval built on Phase 3 data. Few research compounds have a lineage this traceable.
→ Tesamorelin Research Guide · COA available Tesamorelin range
Research use only. Tesamorelin is supplied by Vero Labs strictly as a research compound, not for human or animal use. Every batch is independently third-party lab-tested, with a published Certificate of Analysis (COA) available. Nothing on this page is medical advice or a description of any product’s effects in people.